EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Aberrant TIMP ‐1 production in tumor‐associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma

Paula Duch, Natalia Díaz-Valdivia, Marta Gabasa, Rafael Ikemori, Marselina Arshakyan, Patricia Fernández-Nogueira, Alejandro Llorente, Cristina Teixido iD, Josep Ramírez, Javier Pereda, Lourdes Chuliá-Peris, José Marcelo Galbis und 4 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Paula Duch und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, School of Medicine and Health Sciences, Unit of Biophysics and Bioengineering, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Tissue Inhibitor of Metalloproteinase-1, Lung Neoplasms, Indoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, Sociedad Española de Neumología y Cirugía Torácica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The fibrotic tumor microenvironment is a pivotal therapeutic target. Nintedanib, a clinically approved multikinase antifibrotic inhibitor, is effective against lung adenocarcinoma (ADC) but not squamous cell carcinoma (SCC). Previous studies have implicated the secretome of tumor‐associated fibroblasts (TAFs) in the selective effects of nintedanib in ADC, but the driving factor(s) remained unidentified. Here we examined the role of tissue inhibitor of metalloproteinase‐1 (TIMP‐1), a tumor‐promoting cytokine overproduced in ADC‐TAFs. To this aim, we combined genetic approaches with in vitro and in vivo preclinical models based on patient‐derived TAFs. Nintedanib reduced TIMP‐1 production more efficiently in ADC‐TAFs than SCC‐TAFs through a SMAD3‐dependent mechanism. Cell culture experiments indicated that silencing TIMP1 in ADC‐TAFs abolished the therapeutic effects of nintedanib on cancer cell growth and invasion, which were otherwise enhanced by the TAF secretome. Consistently, co‐injecting ADC cells with TIMP1 ‐knockdown ADC‐TAFs into immunocompromised mice elicited a less effective reduction of tumor growth and invasion under nintedanib treatment compared to tumors bearing unmodified fibroblasts. Our results unveil a key mechanism underlying the selective mode of action of nintedanib in ADC based on the excessive production of TIMP‐1 in ADC‐TAFs. We further pinpoint reduced SMAD3 expression and consequent limited TIMP‐1 production in SCC‐TAFs as key for the resistance of SCC to nintedanib. These observations strongly support the emerging role of TIMP‐1 as a critical regulator of therapy response in solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer-Associated FibroblastsTissue Inhibitor of Metalloproteinase-1Lung NeoplasmsIndolesAdenocarcinoma of LungSmad3 ProteinAnimalsHumansMiceCell Line, TumorTumor MicroenvironmentXenograft Model Antitumor AssaysCell ProliferationCarcinoma, Squamous CellAntineoplastic AgentsFemale

Stichwörter der Autor:innen

SMAD3TIMP‐1cancer‐associated fibroblastfibrosisnintedanibnon‐small‐cell lung cancertherapy resistance

Substanzen

Tissue Inhibitor of Metalloproteinase-1IndolesSmad3 ProteinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biomedicine, School of Medicine and Health Sciences, Unit of Biophysics and Bioengineering, University of Barcelona, Barcelona, Spain.
  • Thoracic Oncology Unit, Hospital Clinic Barcelona, Barcelona, Spain.
  • Pathology Service, Hospital Clinic Barcelona, Barcelona, Spain.
  • August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Biomedical Research Center Network for Respiratory Diseases (CIBERES), Carlos III Health Institute, Madrid, Spain.
  • Department of Physiology, Faculty of Pharmacy, University of Valencia, Burjassot, Spain.

ORCID-Profile: Cristina Teixido, Jordi Alcaraz

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • Sociedad Española de Neumología y Cirugía Torácica
  • Universitat de València
  • Campus Ciències de la Salut de Bellvitge, Universitat de Barcelona
  • National Institutes of Health
  • Ciência sem Fronteiras
  • Fundación Científica Asociación Española Contra el Cáncer

Zitieren

APA

Duch, P., Díaz-Valdivia, N., Gabasa, M., Ikemori, R., Arshakyan, M., Fernández-Nogueira, P., Llorente, A., Teixido, C., Ramírez, J., Pereda, J., Chuliá-Peris, L., Galbis, J. M., Hilberg, F., Reguart, N., Radisky, D. C., & Alcaraz, J. (2024). Aberrant TIMP ‐1 production in tumor‐associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma. Cancer Science. https://doi.org/10.1111/cas.16141

Vancouver

Duch P, Díaz-Valdivia N, Gabasa M, Ikemori R, Arshakyan M, Fernández-Nogueira P, et al. Aberrant TIMP ‐1 production in tumor‐associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma. Cancer Science. 2024. doi:10.1111/cas.16141

BibTeX
@article{Duch2024,
  author = {Duch, Paula and Díaz-Valdivia, Natalia and Gabasa, Marta and Ikemori, Rafael and Arshakyan, Marselina and Fernández-Nogueira, Patricia and Llorente, Alejandro and Teixido, Cristina and Ramírez, Josep and Pereda, Javier and Chuliá-Peris, Lourdes and Galbis, José Marcelo and Hilberg, Frank and Reguart, Noemí and Radisky, Derek C and Alcaraz, Jordi},
  title = {Aberrant TIMP ‐1 production in tumor‐associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16141}
}
Kostenlos starten →